Colony Group LLC lifted its stake in Colgate-Palmolive (NYSE:CL) by 50.9% in the 4th quarter, according to the company in its most recent disclosure with the Securities and Exchange Commission. The firm owned 53,099 shares of the company’s stock after buying an additional 17,909 shares during the period. Colony Group LLC’s holdings in Colgate-Palmolive were worth $3,655,000 as of its most recent filing with the Securities and Exchange Commission.

A number of other large investors also recently modified their holdings of CL. Peddock Capital Advisors LLC acquired a new stake in shares of Colgate-Palmolive in the 4th quarter valued at $34,000. Pacifica Partners Inc. acquired a new position in shares of Colgate-Palmolive during the 4th quarter worth $36,000. Evoke Wealth LLC acquired a new position in shares of Colgate-Palmolive during the 3rd quarter worth $37,000. West Bancorporation Inc. bought a new stake in shares of Colgate-Palmolive during the 4th quarter worth $38,000. Finally, Keebeck Wealth Management LLC bought a new stake in shares of Colgate-Palmolive during the 4th quarter worth $39,000. 77.84% of the stock is currently owned by institutional investors and hedge funds.

Several analysts recently weighed in on CL shares. Deutsche Bank upped their price objective on Colgate-Palmolive from $72.00 to $73.00 and gave the stock a “hold” rating in a research report on Thursday, December 12th. SunTrust Banks restated a “hold” rating and set a $70.00 price objective on shares of Colgate-Palmolive in a research report on Monday, February 3rd. Berenberg Bank restated a “sell” rating and set a $58.00 price objective on shares of Colgate-Palmolive in a research report on Tuesday, February 4th. TheStreet upgraded Colgate-Palmolive from a “c+” rating to a “b” rating in a research report on Friday, January 31st. Finally, Royal Bank of Canada upgraded Colgate-Palmolive from a “sector perform” rating to an “outperform” rating and upped their price objective for the stock from $69.00 to $91.00 in a research report on Monday, February 3rd. Two analysts have rated the stock with a sell rating, eight have given a hold rating and eight have issued a buy rating to the company’s stock. Colgate-Palmolive has a consensus rating of “Hold” and an average price target of $74.73.

Shares of CL opened at $59.89 on Thursday. Colgate-Palmolive has a 12-month low of $58.49 and a 12-month high of $77.41. The business has a 50-day simple moving average of $71.68 and a two-hundred day simple moving average of $69.94. The company has a quick ratio of 0.69, a current ratio of 1.03 and a debt-to-equity ratio of 13.14. The stock has a market cap of $52.31 billion, a PE ratio of 21.78, a PEG ratio of 3.61 and a beta of 0.73.

Colgate-Palmolive (NYSE:CL) last issued its earnings results on Friday, January 31st. The company reported $0.73 earnings per share (EPS) for the quarter, hitting analysts’ consensus estimates of $0.73. Colgate-Palmolive had a return on equity of 1,906.25% and a net margin of 15.08%. The business had revenue of $4.02 billion during the quarter, compared to analysts’ expectations of $3.93 billion. During the same quarter in the prior year, the firm earned $0.74 EPS. The business’s revenue for the quarter was up 5.4% compared to the same quarter last year. On average, equities research analysts expect that Colgate-Palmolive will post 2.96 EPS for the current year.

The company also recently announced a quarterly dividend, which will be paid on Friday, May 15th. Shareholders of record on Monday, April 20th will be issued a $0.44 dividend. This represents a $1.76 dividend on an annualized basis and a yield of 2.94%. The ex-dividend date is Friday, April 17th. This is a boost from Colgate-Palmolive’s previous quarterly dividend of $0.43. Colgate-Palmolive’s dividend payout ratio is presently 60.78%.

In other Colgate-Palmolive news, Chairman Ian M. Cook sold 17,750 shares of the company’s stock in a transaction dated Thursday, January 30th. The stock was sold at an average price of $69.11, for a total value of $1,226,702.50. Following the completion of the transaction, the chairman now owns 1,042,241 shares of the company’s stock, valued at approximately $72,029,275.51. The sale was disclosed in a legal filing with the SEC, which is available through the SEC website. Also, insider Daniel B. Marsili sold 1,092 shares of the company’s stock in a transaction dated Wednesday, March 11th. The stock was sold at an average price of $69.44, for a total value of $75,828.48. Following the completion of the transaction, the insider now directly owns 47,115 shares of the company’s stock, valued at approximately $3,271,665.60. The disclosure for this sale can be found here. In the last ninety days, insiders sold 261,607 shares of company stock valued at $19,590,445. Insiders own 1.14% of the company’s stock.

Colgate-Palmolive Company Profile

Colgate-Palmolive Company, together with its subsidiaries, manufactures and sells consumer products worldwide. The company operates through two segments, Oral, Personal and Home Care; and Pet Nutrition. It offers oral care products, including toothpastes, toothbrushes, and mouthwashes, as well as pharmaceutical products for dentists and other oral health professionals; and personal care products, such as liquid hand soaps, bar soaps, shower gels, deodorants and antiperspirants, skin care products, and shampoos and conditioners.

Featured Story: Do You Need a Fiduciary?

Want to see what other hedge funds are holding CL? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for Colgate-Palmolive (NYSE:CL).

Institutional Ownership by Quarter for Colgate-Palmolive (NYSE:CL)

Receive News & Ratings for Colgate-Palmolive Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Colgate-Palmolive and related companies with MarketBeat.com's FREE daily email newsletter.